UBS Charts a Path Through Legal and Liquidity Challenges

UBS is navigating a complex landscape of legacy legal issues and innovative financial engineering as it approaches a series of critical shareholder and operational milestones. The bank’s strategy is being tested on multiple fronts, from a high-stakes standoff with US investigators to creative solutions for unlocking capital in a challenging private markets environment.

At the heart of the bank’s immediate concerns is a legal blockade that has drawn sharp criticism. UBS is refusing to hand over privileged documents related to Nazi-era accounts from the acquired Credit Suisse to investigator Neil Barofsky, citing insufficient guarantees against new financial claims. This stance has already been criticized by a US Senate committee for a lack of cooperation. The dispute risks escalating to further public hearings in Washington by autumn 2026, potentially complicating the bank’s US operations.

This legal tension forms a critical backdrop to the upcoming Annual General Meeting on April 15 in Basel. Shareholders are set to vote on a proposed dividend of USD 1.10 per share for the 2025 financial year and planned share buybacks of approximately USD 3 billion for 2026. Investors are expected to use the gathering to demand clarity from management on potential provisions for these lingering Credit Suisse liabilities. The bank’s leadership faces the central challenge of balancing attractive capital returns with unresolved legal risks.

Should investors sell immediately? Or is it worth buying UBS?

Simultaneously, UBS is addressing liquidity pressures in its asset management arm through a novel transaction. Its Unified Global Alternatives division plans to sell USD 500 million in securities based on stakes in eight private credit funds. With traditional exits difficult for these evergreen funds, the bank has structured the deal with an insurance wrap covering up to USD 375 million in potential losses. This mechanism secured an A2 investment-grade rating from Moody’s, making the securities tradable. The move highlights how extended holding periods for private equity assets are pushing managers to find creative ways to free up locked capital.

Analysts remain supportive of the broader equity story. Deutsche Bank Research recently reaffirmed its buy rating on UBS shares with a price target of 39 Swiss Francs. They point to an attractive valuation and anticipate regulatory clarity this month regarding Swiss “Too Big To Fail” reforms. The stock currently trades at EUR 35.40, hovering just above its 50-day moving average, though it remains down nearly 12% since the start of the year.

Operationally, the bank delivered a net profit of USD 7.8 billion for the full year 2025, funding the increased cash dividend. The immediate focus now shifts to first-quarter results due on April 29, where analysts anticipate solid net new money inflows, particularly from the APAC and EMEA regions. Looking further ahead, UBS has set a return on CET1 capital target of around 15% by the end of 2026, aiming to raise that to approximately 18% by 2028. The successful delivery of increased synergy targets—now raised to USD 13.5 billion—will be key to determining whether the stock can recover its year-to-date losses.